Department of Clinical Research, Bio-Forum Foundation, 040245 Bucharest, Romania.
Department of Thyroid Pathology, National Institute of Endocrinology CI Parhon, 011863 Bucharest, Romania.
Mol Med Rep. 2019 Sep;20(3):2332-2338. doi: 10.3892/mmr.2019.10453. Epub 2019 Jul 1.
Benign thyroid nodules are among the most common endocrine disorders. Recent advances in diagnostic imaging and pathology have significantly contributed to better risk stratification of thyroid nodules. However, current treatment options, beyond surgical approaches are limited. The following placebo-controlled study presents, to the best of our knowledge, the first results of a non-invasive therapy for benign thyroid nodules. The efficacy and safety of a supplement containing spirulina, curcumin and Boswellia in euthyroid patients with benign thyroid nodules, was assessed by a 3 month, double-blind, placebo-controlled study which was completed by 34 patients. Patients with benign (FNAB documented) single thyroid nodules between 2 and 5 cm were evaluated in a prospective placebo-controlled cross-over trial, across 12 weeks (3 visits with six-week intervals). At each visit, the target thyroid nodule was recorded in two dimensions. In addition, plasma levels of thyroid stimulating hormone, free thyroxine and copper were assessed. The mean initial nodule area at V1 was 4.38±3.14 cm2, at V2 3.87±2.79 cm2, and at V3 3.53±2.84 cm2; P<0.04. Administration of the active substances (n=34) was followed by a mean area decrease of 0.611 cm2±0.933 (SD), while placebo administration (n=29) was followed by a mean decrease of 0.178 cm2±0.515 (SD), (P=0.027). The presented findings suggest that the combination of spirulina-curcumin-Βoswellia is effective in reducing the size of benign thyroid nodules. However, additional studies are needed in order to elucidate the exact mechanisms through which the suggested supplement facilitates a decrease in the size of benign thyroid nodules.
良性甲状腺结节是最常见的内分泌疾病之一。近年来，诊断影像学和病理学的进步极大地促进了甲状腺结节的风险分层。然而，除了手术方法之外，目前的治疗选择是有限的。以下是一项安慰剂对照研究，就我们所知，这是首次针对良性甲状腺结节的非侵入性治疗方法。一项含有螺旋藻、姜黄素和 Boswellia 的补充剂对甲状腺功能正常的良性甲状腺结节患者的疗效和安全性进行了评估，这是一项为期 3 个月的双盲、安慰剂对照研究，共有 34 名患者完成了该研究。在一项前瞻性安慰剂对照交叉试验中，评估了 12 周（3 次就诊，间隔 6 周）内直径为 2 至 5 厘米的良性（FNAB 记录）单发甲状腺结节的患者。在每次就诊时，以二维方式记录目标甲状腺结节。此外，还评估了甲状腺刺激激素、游离甲状腺素和铜的血浆水平。V1 时的平均初始结节面积为 4.38±3.14cm2，V2 时为 3.87±2.79cm2，V3 时为 3.53±2.84cm2；P<0.04。活性物质（n=34）给药后平均面积减少 0.611cm2±0.933（SD），而安慰剂给药（n=29）后平均面积减少 0.178cm2±0.515（SD），（P=0.027）。研究结果表明，螺旋藻-姜黄素-Boswellia 联合使用可有效缩小良性甲状腺结节的大小。然而，需要进一步的研究来阐明该补充剂促进良性甲状腺结节缩小的确切机制。
